2Brownlee M. The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes,2005,54(6): 1 615 -1 625.
3UK Prospective Diabetes Study Group Prospective Diabetes Study16 :Overview of 6 years'therapy of type Ⅱ diabetes,a progressive disease[J]. Diabetes, 1995,44: 1 249 - 1 258.
4Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes[ J]. N Engl J Med,2003,348(5): 383 - 393.
6Hotta N, Akanuma Y, Akanuma Y, et al. Long -term clinical effects of cpalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3 - year, multicenter, comparative Aldose Reductase Inhibitor - Diabetes Complications Trial [ J ]. Diabetes Care, 2006,29(7): 1 538-1 544.
7Ziegler D,Nowak H,Kemp ler P,et al. Treatment of syrup - tomatic diabetic polyneuropathy with the antioxidant α - lipoic acid : a meta analysisl [ J]. Diabet Med,2004,21:114 - 121.
9Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCI on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus [ J ]. J Diabetes Complications, 2008,22 ( 4 ) : 241 - 245.
10Raskin J, Pritehett JL, Wang F, et al. A double - blind, multicenter trial comparing duloxetine with placebo in the treatment of diabetic peripheral neuropathie pain[ J]. Diabetes,2005,54: 126.
